2026 Joel Moss: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	115	789	700	494	429	761	47965

Overview

Joel Moss is affiliated with the National Institutes of Health in the United States. Their research spans primarily the field of Medicine, with substantial contributions to subfields including Physiology, Oncology, Pulmonary and Respiratory Medicine, Immunology, and Radiology, Nuclear Medicine and Imaging.

The main areas of study that characterize Joel Moss's work include:

Tuberous Sclerosis Complex Research
PARP inhibition in cancer therapy
Histiocytic Disorders and Treatments
Toxin Mechanisms and Immunotoxins
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Medical Imaging and Pathology Studies
Calcium signaling and nucleotide metabolism

Joel Moss has contributed to several research articles published in notable venues. Some recent papers include:

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations (2021), published in Pediatric Neurology
ADP-ribosyltransferases, an update on function and nomenclature (2021), published in FEBS Journal
The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis (2020), published in Journal of Biological Chemistry
T2-weighted Lung Imaging Using a 0.55-T MRI System (2021), published in Radiology Cardiothoracic Imaging
Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts (2020), published in Thorax

Frequent coauthors with whom Joel Moss collaborates include:

Thomas N. Darling
Jiro Kato
Evan G. DeRenzo
Eric A. Singer
Isao Nagaoka

Joel Moss's work is published repeatedly in several key journals, including:

CHEST Journal
Juntendo Medical Journal
Journal of Investigative Dermatology
bioRxiv (Cold Spring Harbor Laboratory)
Journal of the American Academy of Dermatology

Best Publications

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Francis X. McCormack;Yoshikazu Inoue;Joel Moss;Lianne G. Singer

1175
Citations
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298

M. Tesauro;W. C. Thompson;P. Rogliani;L. Qi

764
Citations
Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.

William D. Travis;Kazuhiro Matsui;Joel Moss;Victor J. Ferrans

715
Citations
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

Hope Northrup;Mary E. Aronow;E. Martina Bebin;John Bissler

652
Citations
Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators

Basil P. Hubbard;Ana P. Gomes;Ana P. Gomes;Han Dai;Jun Li

652
Citations
Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site.

R. E. West;J. Moss;M. Vaughan;T. Liu

627
Citations
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Jay H. Ryu;Joel Moss;Gerald J. Beck;Jar Chi Lee

601
Citations
Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin

C. E. Vreim;M. Wu;R. G. Crystal;A. S. Buist

561
Citations
Molecules in the ARF Orbit

Joel Moss;Martha Vaughan

498
Citations
Cytokine-mediated Transcriptional Induction of the Human Inducible Nitric Oxide Synthase Gene Requires Both Activator Protein 1 and Nuclear Factor κB-binding Sites

Joanna Marks-Konczalik;Shan C. Chu;Joel Moss

458
Citations
Pulmonary Nontuberculous Mycobacterial Disease: Prospective Study of a Distinct Preexisting Syndrome

Richard D. Kim;David E. Greenberg;Mary E. Ehrmantraut;Shireen V. Guide

455
Citations
STRUCTURE AND FUNCTION OF ARF PROTEINS : ACTIVATORS OF CHOLERA TOXIN AND CRITICAL COMPONENTS OF INTRACELLULAR VESICULAR TRANSPORT PROCESSES

Joel Moss;Martha Vaughan

453
Citations
Oxidation of either methionine 351 or Methionine 358 in alpha-1-Antitrypsin causes loss of anti-neutrophil elastase activity

Clifford Taggart;Daniel Cervantes-Laurean;Geumsoo Kim;Noel G. McElvaney

401
Citations
beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein.

Richard T. Premont;Audrey Claing;Nicolas Vitale;Jennifer L. R. Freeman

378
Citations
Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex.

Joel Moss;Nilo A. Avila;Pauline M. Barnes;Ruth A. Litzenberger

376
Citations
Adp‐Ribosylation of Guanyl Nucleotide‐Binding Regulatory Proteins by Bacterial Toxins

Joel Moss;Martha Vaughan

334
Citations
β-Arrestin-mediated ADP-ribosylation Factor 6 Activation and β2-Adrenergic Receptor Endocytosis

Audrey Claing;Wei Chen;William E. Miller;Nicolas Vitale

319
Citations
Stimulation by nitric oxide of an NAD linkage to glyceraldehyde-3-phosphate dehydrogenase

Lee J. McDonald;Joel Moss

318
Citations
Functional incorporation of ganglioside into intact cells: induction of choleragen responsiveness.

Joel Moss;Peter H. Fishman;Vincent C. Manganiello;Martha Vaughan

316
Citations
Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators

B. P. Hubbard;A. P. Gomes;H. Dai;J. Li

1
Citations